Mustang Bio Inc Cash Flow Conversion Efficiency
Mustang Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Mustang Bio Inc (MBIO) has a cash flow conversion efficiency ratio of -0.128x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-967.00K) by net assets ($7.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mustang Bio Inc (2016–2025)
Cash flow conversion efficiency of Mustang Bio Inc from 2016 to 2025. This chart illustrates how Mustang Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Mustang Bio Inc for real-time trading data and today's change.
Mustang Bio Inc Cash Flow Conversion Ratio Explained
Mustang Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mustang Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mustang Bio Inc ranked by their cash flow conversion efficiency. Also see MBIO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innovotech Inc
V:IOT
|
-0.247x |
|
WEBUY GLOBAL LTD. Ordinary Shares
NASDAQ:WBUY
|
-0.215x |
|
Australian Silica Quartz Group Ltd
F:4B4
|
-0.076x |
|
Tartana Minerals Ltd
AU:TAT
|
-0.217x |
|
Unity Biotechnology Inc
NASDAQ:UBX
|
31.010x |
|
Kridhan Infra Limited
NSE:KRIDHANINF
|
-0.004x |
|
Ordissimo
PA:ALORD
|
0.067x |
|
Videndum Plc
LSE:VID
|
-0.201x |
Annual Cash Flow Conversion Efficiency for Mustang Bio Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Mustang Bio Inc from 2016 to 2025. Review Mustang Bio Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.53 Million | $-5.26 Million | -0.552x | -118.75% |
| 2024-12-31 | $-3.87 Million | $-11.41 Million | 2.946x | +100.73% |
| 2023-12-31 | $123.00K | $-49.48 Million | -402.252x | -28506.97% |
| 2022-12-31 | $46.27 Million | $-65.07 Million | -1.406x | -194.50% |
| 2021-12-31 | $112.40 Million | $-53.67 Million | -0.477x | -25.94% |
| 2020-12-31 | $98.44 Million | $-37.32 Million | -0.379x | +41.69% |
| 2019-12-31 | $51.65 Million | $-33.58 Million | -0.650x | -22.96% |
| 2018-12-31 | $36.40 Million | $-19.24 Million | -0.529x | -144.33% |
| 2017-12-31 | $59.83 Million | $-12.95 Million | -0.216x | -27.23% |
| 2016-12-31 | $24.28 Million | $-4.13 Million | -0.170x | -- |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more